Biocon (BIOLIN, NR/BB/BB) growth supported by Biosmiliars. Q3 results neutral for spread.
Looking ahead, the Biosimilars business (58% of rev.) should support and uplift for the group versus the first half with 8 approvals and 14 new launches on the pipe. Results neutral for spreads.

Find more articles and bullets on these widgets:
WTI futures are trading higher today as the contract extends recent gains. A stronger reversal to the upside would refocus attention on key short-term resistance at $76.41, the Oct 8 high. Initial firm resistance is unchanged at $71.97. A bear threat in Gold remains present. The yellow metal traded sharply lower on Dec 18 and the move undermines a recent bull theme. A resumption of weakness would open key support at $2536.9, the Nov 14 low.